

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
120<sup>th</sup> Meeting of the Blood Products Advisory Committee  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Meeting Link: <https://collaboration.fda.gov/bpac0319>

## AGENDA

March 20, 2019

8:30 a.m.	Call to Order and Opening Remarks Introduction of Committee	Richard Kaufman, M.D. Chair
8:40 a.m.	Conflict of Interest Statement	Prabhakara Atreya, Ph.D. Designated Federal Officer
<b>Topic I:</b>	<b>Evaluation of Strategies to Reduce the Risk of Zika Virus (ZIKV) Transmission by Blood and Blood Components</b>	
8:45 a.m.	Evaluation of Strategies to Reduce the Risk of ZIKV Transmission by Blood and Blood Components	Caren Chancey, Ph.D. OBRR, FDA (15')
9:00 a.m.	Update on the Current Status of the ZIKV Epidemic	Marc Fischer, M.D. Centers for Disease Control and Prevention (45')
9:45 a.m.	Questions for the Speakers	(10')
9:55 a.m.	AABB ZIKV Biovigilance Network	Srijana Rajbhandary, M.P.H. AABB (20')
10:15 a.m.	Break	(15')
10:30 a.m.	Current Consideration for Reducing the Risk of Transfusion Transmitted ZIKV	David Leiby, Ph.D. OBRR, FDA (30')
11:00 am	Questions for the Speakers	(10')
11:10 a.m.	Open Public Hearing	(30')
11:40 a.m.	Open Committee Discussion FDA Questions for the Committee	(60')
12:45 p.m.	Lunch	(60')

3/18/19

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
120<sup>th</sup> Meeting of the Blood Products Advisory Committee  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Meeting Link: <https://collaboration.fda.gov/bpac0319>

## AGENDA

### **Topic II: Review of the Research Programs in the Laboratory of Biochemistry and Vascular Biology, Division of Blood Components and Devices, OBRR**

1:40 p.m.	Conflict of Interest Statement	Prabhakara Atreya, Ph.D. Designated Federal Officer
1:45 p.m.	Overview of CBER Research Programs	Monica Young, Ph.D. CBER, FDA (10')
1:55 p.m.	Overview of OBRR Research Programs	CD Atreya, Ph.D. OBRR, FDA (10')
2:05 p.m.	Overview of the Division of Blood Components and Devices Research Programs	Orieji Illoh, M.D. OBRR, FDA (10')
2:15 p.m.	Research Programs in the Laboratory of Biochemistry and Vascular Biology	Abdu Alayash, Ph.D. OBRR, FDA (45')
3:00 p.m.	Questions for the Speakers	(15')
3:15 p.m.	Open Public Hearing	(30')
3:45 p.m.	Break	(15')
4:00 p.m.	Closed Committee Discussion	(45')
4:45 p.m.	Adjournment	

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
120<sup>th</sup> Meeting of the Blood Products Advisory Committee  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Meeting Link: <https://collaboration.fda.gov/bpac0319>

## AGENDA

March 21, 2019

8:30 a.m.	Call to Order and Opening Remarks Introduction of Committee	Richard Kaufman, M.D. Chair
8:40 a.m.	Conflict of Interest Statement	Prabhakara Atreya, Ph.D. Designated Federal Officer
<b>Topic III:</b>	<b>Blood Donation Policies Regarding Men Who Have Sex with Men (MSM)</b>	
<b>Topic III A:</b>	<b>Update on Donor Deferral Policies and Donor HIV Risk Questionnaire Study</b>	
8:45 a.m.	Blood Donation Policies Regarding MSM	Anne Eder, M.D., Ph.D. OBRR, FDA (20')
9:05 a.m.	International Perspectives on Blood Donor Eligibility, MSM	Mindy Goldman, M.D. Canadian Blood Services (20')
9:25 a.m.	Epidemiology of HIV in the United States, 2019	John Brooks, M.D. Centers for Disease Control and Prevention (20')
9:45 a.m.	Overview of the Transfusion-Transmissible Infections Monitoring System (TTIMS)	Alan Williams, Ph.D. OBE, FDA (20')
10:05 a.m.	Questions for Speakers	(15')
10:20 a.m.	Break	(15')
10:35 a.m.	The Donor HIV Risk Questionnaire Study	Barbee Whitaker, Ph.D. OBE, FDA (20')
11:05 a.m.	Questions for speaker	(15')
11:25 a.m.	Open Public Hearing	(30')

3/18/19

# FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research  
*120<sup>th</sup> Meeting of the Blood Products Advisory Committee*  
Great Room, Building 31  
FDA White Oak Campus  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Meeting Link: <https://collaboration.fda.gov/bpac0319>

## AGENDA

11:55 a.m.	Open Committee Discussion FDA Questions for the Committee	(35')
12:30 p.m.	Lunch	(60')
<b>Topic III B:</b>	<b>Pathogen Reduction of Platelet Donations as an Alternative Procedure to MSM Donor Deferral</b>	
1:30 p.m.	Pathogen Reduction of Platelet Donations as an Alternative Procedure to MSM Donor Deferral	Carlos Villa, M.D., Ph.D. OBRR, FDA (20')
1:50 p.m.	Proposal for Pathogen Reduction of Platelet Donations from MSM	James AuBuchon, M.D. Bloodworks Northwest (40')
2:30 p.m.	Questions for Speakers	(15')
2:45 p.m.	Break	(15')
3:00 p.m.	Open Public Hearing	(60')
4:00 p.m.	Open Committee Discussion FDA Questions for the Committee	(60')
5:00 p.m.	Adjournment	